<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02202902</url>
  </required_header>
  <id_info>
    <org_study_id>AOR12017</org_study_id>
    <secondary_id>2013-A01023-42</secondary_id>
    <nct_id>NCT02202902</nct_id>
  </id_info>
  <brief_title>Cardiac Steatosis in Cushing's Syndrome</brief_title>
  <acronym>CORTICOEUR</acronym>
  <official_title>Evaluation of Cardiac Steatosis in Cushing's Syndrome. A 1H-Magnetic Resonance Spectroscopy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at evaluating the myocardial triglyceride content and cardiac structure and
      function, using 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging, in
      patients with Cushing's syndrome before and after treatment and in age-, sex- and BMI-matched
      healthy volunteers. The investigators make the hypothesis that Cushing's syndrome patients
      compared to healthy subjects present with excess lipid storage in cardiac myocytes,
      reversible upon correction of hypercortisolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite skeletal muscle atrophy, Cushing's syndrome patients have an increased Left
      Ventricular mass, reversible upon correction of the hypercortisolism. This may be due to
      cardiac steatosis, previously demonstrated in patients with diabetes mellitus. This study
      aims at evaluating the myocardial triglyceride content and cardiac structure and function,
      using 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging (CMRI), in
      patients with Cushing's syndrome and in age-, sex- and BMI-matched healthy volunteers. The
      patients will be stratified into two groups in function of the presence or absence of
      diabetes mellitus or impaired glucose and will be evaluated twice: before and 6 months after
      efficient treatment of Cushing's syndrome. We make the hypothesis that Cushing's syndrome
      patients compared to healthy subjects have excess lipid storage in cardiac myocytes
      irrespectively of the glucose homeostasis status, and that this lipid content will decrease
      after the correction of hypercortisolism.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular (LV) intramyocardial triglyceride / water ratio LV intramyocardial triglyceride / water ratio</measure>
    <time_frame>Assessed twice in patients - before and 6 months after treatment - and once in volunteers</time_frame>
    <description>Intramyocardial triglyceride content will be assessed by 1H magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular intramyocardial fatt fraction (Dixon)</measure>
    <time_frame>Assessed twice in patients - before and 6 months after treatment - and once in volunteers</time_frame>
    <description>In/Out of Phase Imaging (Dixon)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous and visceral abdominal fatt</measure>
    <time_frame>Assessed twice in patients - before and 6 months after treatment - and once in volunteers</time_frame>
    <description>ISubcutaneous and visceral abdominal fat masses were determined from abdominal axial images at the L3 to L4 level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac morphology and function</measure>
    <time_frame>Assessed twice in patients - before and 6 months after treatment - and once in volunteers</time_frame>
    <description>LV mass index, LA, LV and Right Ventricular (RV) ejection fractions and LV and RV stroke volumes assessed by Cardiac Magnetic Resonance Imaging (CMRI)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Endocrine System Disease</condition>
  <condition>Cardiovascular Imaging</condition>
  <arm_group>
    <arm_group_label>Group 1 : 1H magnetic resonance spectroscopy and CMRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 : Cushing's syndrome patients with diabetes mellitus or glucose intolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 : 1H magnetic resonance spectroscopy and CMRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2: Cushing's syndrome patients with normal glucose intolerance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 : 1H magnetic resonance spectroscopy and CMRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>age-, sex- and BMI-matched healthy volunteers</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1H magnetic resonance spectroscopy and CMRI</intervention_name>
    <description>Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment</description>
    <arm_group_label>Group 1 : 1H magnetic resonance spectroscopy and CMRI</arm_group_label>
    <arm_group_label>Group 2 : 1H magnetic resonance spectroscopy and CMRI</arm_group_label>
    <other_name>Before and after Treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1H magnetic resonance spectroscopy and CMRI</intervention_name>
    <description>Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment</description>
    <arm_group_label>Group 3 : 1H magnetic resonance spectroscopy and CMRI</arm_group_label>
    <other_name>Once</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  group 1 and 2: patients with overt Cushing's syndrome, with 24-hour urinary free
             cortisol excretion over the two fold of the upper limit of the normal, with (group 1)
             or without (group 2) diabetes mellitus or glucose intolerance

          -  group 3: healthy volunteers matched for age, sex and BMI with the patients of the
             group 2

        Exclusion Criteria:

          -  contraindication of MRI

          -  hypersensitivity to gadolinium

          -  acute myocardial ischemia

          -  renal insufficiency (creatinin clearance 30 mL/min/l,73m2)

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe CHANSON, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP, Bicêtre Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philippe CHANSON, MD, PhD</last_name>
    <phone>+33 (0)1 45 21 37 05</phone>
    <email>philippe.chanson@bct.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter KAMENICKY, MD</last_name>
    <phone>+33 (0)1 45 21 37 06</phone>
    <email>peter.kamenicky@bct.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AP-HP, Bicêtre Hospital</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter KAMENICKY, MD</last_name>
      <phone>+33 (0)1 45 21 37 06</phone>
      <email>peter.kamenicky@bct.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2014</study_first_submitted>
  <study_first_submitted_qc>July 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2014</study_first_posted>
  <last_update_submitted>September 28, 2016</last_update_submitted>
  <last_update_submitted_qc>September 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cushing's syndrome</keyword>
  <keyword>cardiac steatosis</keyword>
  <keyword>intramyocardial triglyceride content</keyword>
  <keyword>1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging</keyword>
  <keyword>Left Ventricularly hypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Cushing Syndrome</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

